AOA Dx is proud to announce the company has been chosen as a finalist for Massachusetts Innovation Network’ signature innovation competition, The Eddies. Finalists will have the chance to participate in this 5-month, no-cost, no-equity innovation-support program that includes individualized mentoring, strategic guidance, leadership education, and connections to resources.

“The Massachusetts innovation ecosystem is so rich in amazing companies and technologies. It’s a privilege to be considered amongst this group of trailblazing founders and connect with great mentors in the community.”  said Oriana Papin-Zoghbi, CEO and Co-founder of AOA Dx.

The Eddies (formerly known as NE Innovation Awards) is the oldest and longest running innovation competition in New England. They are open to New England based startups with a working prototype of a ground-breaking product or technology and not more than 150 employees. The objective of this incredible program is to help early-stage startups (pre-Series C) take the next steps in their commercialization journey.

The Eddies finalists are handpicked by a seasoned group of independent, experienced judges, all successful innovators, who evaluated the teams on their innovation disruption and prospect to affect positive change for their users, industries, and markets. There are six innovation tracks the finalists fall into and are listed below in their respective categories.

All Finalists will demonstrate their Innovation and deliver a 3-minute (in-person) Presentation Pitch to Judges and members of the Innovation Ecosystem, at The Eddies Innovation Showcase on Thursday, October 6th. Recognition for all Finalists as well as Award Announcements will be made during The Eddies Evening of Innovation on Thursday, November 3rd.

About AOA Dx Inc.
AOA Dx Inc (AOA Inc) is a US company, with teams based in Boston, New York and London developing cancer diagnostics in the field of women’s health. AOA Dx Inc, a female led company, is committed to bringing the first accurate early stage liquid biopsy ovarian cancer diagnostic test to market that will improve clinical practice, help reduce patient mortality and deliver cost savings to payers. More information can be found at www.aoadx.com.

Contact
Corporate Communications
info@aoadx.com